Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 3/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.40 |
| ▸ | AGL | P35573 | 1/20 | 0.34 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | FUCA1 | P04066 | 1/20 | 0.33 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL27663777 | 0.86 | CHRNB2 (0.41) | CHRNB2CHRNA4 | |
| Trifluoroacetic Acid SCHEMBL31085834 | 0.83 | CHRNB2 (0.43) | CHRNB2CHRNA4KDM1ASLC1A2 | |
| Trifluoroacetic Acid SCHEMBL29134796 | 0.83 | CHRNB2 (0.43) | CHRNB2CHRNA4KDM1ASLC1A2 | |
| Oxalic Acid SCHEMBL4185610 | 0.82 | AGL (0.39) | AGLSLC1A2 | |
| Oxalic Acid SCHEMBL2112772 | 0.82 | AGL (0.39) | AGLSLC1A2 | |
| Trifluoroacetic Acid SCHEMBL17165596 | 0.82 | CHRNB2 (0.37) | CHRNB2CHRNA4AGLFUCA1 | |
| SCHEMBL640198 | 0.79 | — | — | |
| SCHEMBL6946814 | 0.79 | — | — | |
| SCHEMBL1189849 | 0.79 | — | — | |
| Trifluoroacetic Acid SCHEMBL28631777 | 0.78 | SLC1A2 (0.38) | CHRNB2CHRNA4KDM1ASLC1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7504390-B2 | Benzoxazepine derivatives and their use as AMPA receptor stimulators | N.V. ORGANON (NL) | 2009-03-17 | — | — | US | disclosed |
| US-20080139529-A1 | BENZOXAPZEPINE DERIVATIVES AND THEIR USE AS AMPA RECEPTOR STIMULATORS | N.V. ORGANON (NL) | 2008-06-12 | — | — | US | disclosed |
| EP-1399450-B1 | BENZOXAZEPINE DERIVATIVES AND THEIR USE AS AMPA RECEPTOR STIMULATORS | ORGANON NV (NL) | 2008-03-19 | — | — | EP | disclosed |
| US-7307073-B2 | Benzoxazepines derivatives and their use as AMPA receptor stimulators | N.V. ORGANON (NL) | 2007-12-11 | — | — | US | disclosed |
| CN-1257908-C | Benzoxazepine derivatives and their use as AMPA receptor stimulators | AKZO NOBEL NV (NL) | 2006-05-31 | — | — | CN | disclosed |
| US-20040171605-A1 | Benzoxazepines derivatives and their use as ampa receptor stimulators | MERCK SHARP & DOHME B.V. (NL) | 2004-09-02 | — | — | US | disclosed |
| CN-1514835-A | Benzoxazepine derivatives and their use as AMPA receptor stimulators | ��˹��ŵ�� | 2004-07-21 | — | — | CN | disclosed |
| EP-1399450-A1 | BENZOXAZEPINE DERIVATIVES AND THEIR USE AS AMPA RECEPTOR STIMULATORS | Akzo Nobel N.V. (NL) | 2004-03-24 | — | — | EP | disclosed |
| WO-2002100865-A1 | BENZOXAZEPINE DERIVATIVES AND THEIR USE AS AMPA RECEPTOR STIMULATORS | AKZO NOBEL N.V. (NL) | 2002-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040171605-A1 | Benzoxazepines derivatives and their use as ampa receptor stimulators | CHRNA4, CHRNA10, CHRNA9 | CHRNB2 56/4885CHRNA4 1/4885AGL 4317/4885 |
| US-20080139529-A1 | BENZOXAPZEPINE DERIVATIVES AND THEIR USE AS AMPA RECEPTOR STIMULATORS | GRIN1, GRIA4, CHRNA4 | CHRNB2 53/4885CHRNA4 3/4885AGL 4717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.